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Abstract
Escherichia coli’s heat-labile enterotoxin (Etx) and its non-toxic B subunit (EtxB) have been characterized as adjuvants capable of enhancing T cell
responses to co-administered antigen. Here, we investigate the direct effect of intravenously administered EtxB on the size of the dendritic and mye-
loid cell populations in spleen. EtxB treatment appears to enhance the development and turnover of dendritic and myeloid cells from precursors within
the spleen. EtxB treatment also gives a dendritic cell (DC) population with higher viability and lower activation status based on the reduced expression
of MHC-II, CD80 and CD86. In this respect, the in vivo effect of EtxB differs from that of the highly inflammatory mediator lipopolysaccharide. In in vi-
tro bone marrow cultures, EtxB treatment was also found to enhance the development of DC from precursors dependent on Flt3L. In terms of the
in vivo effect of EtxB on CD4 and CD8 T cell responses in mice, the interaction of EtxB directly with DC was demonstrated following conditional deple-
tion of CD11c+ DC. In summary, all results are consistent with EtxB displaying adjuvant ability by enhancing the turnover of DC in spleen, leading to
newly mature myeloid and DC in spleen, thereby increasing DC capacity to perform as antigen-presenting cells on encounter with T cells.
Keywords: dendritic cells T cells cell activation adjuvant enterotoxin
Introduction
Dendritic cells (DC) are antigen-presenting cells which take up foreign
pathogens and present antigens to T cells, so initiating an immune
response to the invading pathogen. In the context of vaccination, with
the aim of pre-exposing the immune system to antigens from patho-
gens of interest, the type and magnitude of a T cell response can be
modulated through use of adjuvants. Most adjuvants function at the
time of antigen encounter with DC. They act either to stabilize the
antigen and increase the probability of uptake by DC or to directly
affect the DC, ensuring the antigen is encountered in an environment
supporting a strong antigen-specific response.
Heat-labile enterotoxin (Etx), produced by enterotoxigenic Escher-
ichia coli, and its non-toxic B subunit (EtxB) are known to be strong
mucosal adjuvants although the mechanism by which they act as an
adjuvant is not yet known [1]. Enterotoxin is a hetero-oligomeric AB5
toxin with the non-toxic B subunit binding to the ganglioside GM1 on
the surface of the cell facilitating translocation of the A subunit into
the cytoplasm. Binding of EtxB to the cell surface appears to be an
immunomodulatory process in itself [2] and GM1-binding by EtxB
can up-regulate antigen presentation [3]. While EtxB binds most
strongly to GM1, it also binds to other cell surface molecules includ-
ing asialo-GM1, GD1b-ganglioside and lactosylceramide. The contri-
bution of these binding interactions to adjuvanticity is, however, not
known [4]. GM1 is ubiquitously expressed on most cells although
expression varies across different cell types. For example, two sub-
sets of monocytes with differing endocytic capacity can be identified
based on the GM1 expression [5]. Following EtxB binding, EtxA deliv-
ers a toxic effect into the cell cytoplasm through activation of the cyc-
lic AMP (cAMP) pathway. In the epithelial cells of the intestine, this
leads to the opening of ion channels and resulting diarrhoea [6].
Several previous studies have demonstrated the immunomodula-
tory effects of both Etx and EtxB, with emphasis on their adjuvanting
properties [7–10]. Previous studies on EtxB as an immunomodulator
and adjuvant have focused on its role in T cell responses [11–13],
and on its interaction with antigen-presenting cells like macrophages
[14, 15], and B cells [16, 17]. Previous studies on the interaction of
EtxB with DC showed that binding to GM1 was essential for
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EtxB-mediated antigen presentation by JAWSII, an immortalized mur-
ine bone marrow-derived DC line [18]. When DC generated in GM-
CSF-induced bone marrow cultures were exposed to EtxB ovalbumin
(-OVA) conjugates, they induced superior CD8+ T cell responses over
OVA alone, but did not induce DC maturation [19]. Despite these ear-
lier studies, there has been no investigation of the effect of EtxB on
DC in vivo.
A range of DC subsets can now be identified on the basis of their
tissue of residence, functional capacity and marker expression. Sple-
nic dendritic and myeloid subsets are very well characterized and can
be identified on the basis of expression of the integrins CD11b and
CD11c, as well as CD8a (or CD8) and MHC-II. Conventional (c)DC are
CD11c+ MHC-II+ cells, with CD8 CD11b+ and CD8+ CD11b subsets
distinguishable. In terms of function, CD8+ cDC are cross-presenting,
interleukin (IL)-12-producing cells resident in the T cell zone of spleen
[20], while CD8 cDC are located in the marginal zone, migrating to T
cell zones following antigen encounter [21]. Plasmacytoid (p)DC are
circulating type I interferon-producing cells and can be identified by
their CD11clo CD11b CD8 MHC-II+ phenotype [22].
Here, we investigate the effect of EtxB administration on subsets of
cDC and pDC and their precursors, as well as L-DC, myeloid cells and
myeloid precursors in vivo. Furthermore, we investigate the ability of
EtxB to enhance T cell activation upon administration to mice, and
determine the importance of DC in EtxB-induced T cell activation in vivo.
Materials and methods
Animals
Specific pathogen-free C57BL/6J (H-2Kb) female mice aged 6 weeks
were obtained from the Australian National University (ANU) Bioscienc-
es Services (Canberra, ACT, Australia). BALB/c CD11c-diptheria toxin
receptor (DTR) transgenic (tg) mice, C57BL/6.Tg(TcraTcrb)1100Mjb
(OT-I) and C57BL/6.SJL/J.OT-II.CD45.1 (OT-II) were obtained from the
Walter and Eliza Hall Institute (WEHI; Parkville, VIC, Australia). Mice
were housed and handled according to protocols approved by the Ani-
mal Experimentation Ethics Committee at the ANU (Canberra, ACT, Aus-
tralia). For tail vein injections (i.v.), substances were administered in
200 ll, using a 26G syringe. For intranasal vaccination, mice were
anaesthetized by inhalation with 1-ml vaporized methoxyflurane (Penth-
raneTM; Abbott Laboratories, North Ryde, NSW, Australia) and given
10 ll per nostril using a micropipette.
Expression and purification of EtxB
Cultures of E. coli G6 expressing pMMB68, which encodes wild-type
EtxB [23], were cultured at 37°C, induced with 0.5 mM isopropyl b-D-1-
thiogalactopyranoside and lysed using a French Press (Thermo Electron
Corporation, Waltham, MA, USA). After extensive testing of purification
procedures, one method was adopted as optimal. Subsequently, EtxB
(in 20 mM NaCl, 25 mM Tris–HCl, pH 8.0) was purified using cation
and anion exchange chromatography (4°C, elution step gradient using
250 mM NaCl, 25 mM Tris–HCl, pH 8.0, with a 10 column volume 1,5-
pentanediol wash during the first cation exchange), before lipopolysac-
charide (LPS) depletion using Endotrap Red columns (Lonza, Walkers-
ville, MD, USA). Purified EtxB contained ≤0.04 endotoxin units per lg
protein as determined by a kinetic chromogenic Limulus amoebocyte
lysate assay (AMS Laboratories, Silverwater, NSW, Australia). EtxB
(1.58 mg/ml) was utilized either unheated or heat inactivated at 95°C
for 10 min. in Eppendorf tubes and stored short-term at 20°C and
long-term at 80°C in PBS.
Generation of bone marrow chimaeras
To generate bone marrow chimaeras, 6-week-old C57BL/6J mice were
lethally irradiated using two doses of 550 cGy, 3 hrs apart. Mice were
rested for a few hours before being reconstituted i.v. with 5 9 106 T cell-
depleted CD11c-DTR-tg bone marrow cells. On the following day, mice
were given 100 ll of anti-Thy-1 (T24) ascites intraperitoneally (i.p.) to
deplete radioresistant T cells. Mice were given antibiotic water (106U poly-
myxin B sulphate and 1.1 g neomycin sulphate; L sterile milliQ water) for
2 weeks following irradiation and left for at least 8 weeks before use.
Preparation of cell suspensions
Bone marrow was flushed from the bone cavity using a 26G needle to
deliver Dulbecco’s modified eagle medium supplemented with 10% FCS
as described previously (sDMEM) [23]. Spleen, lymph nodes (mediasti-
nal and mesenteric) and bone marrow were dissociated by pressing tis-
sue through a fine wire sieve. Red blood cell lysis, using a hypotonic
buffer containing 140 mM ammonium chloride and 17 mM Tris-Base at
pH 7.4 was performed on the spleen and bone marrow. For cell count-
ing, trypan blue staining was used to exclude dead cells.
Antibody staining
Cells were resuspended to a final concentration of 1–5 9 105 cells/
100 ll, plated in the wells of a 96-well microtitre plate, and pelleted by
centrifugation. For FcR blocking, 25 ll FACS buffer containing 40 lg/ml
of ‘Fc block’ specific for FccII/IIIR (CD32/CD16; eBioscience, San Diego,
CA, USA). Cells were washed twice with FACS buffer, resuspended in an
antibody cocktail diluted in FACS buffer, incubated on ice for 20 min. and
then washed in FACS buffer. Antibodies were all from eBioscience
(San Diego, CA, USA), BD Pharmingen (San Diego, CA, USA) or BioLegend
(San Gabriel, CA, USA), and included FITC- or APC-conjugated CD11c
(clone N418), PE-Cy7-conjugated CD11b (clone M1/70), APC- PE- or
FITC-conjugated CD8a (clone 53-6.7), PE- FITC- or biotin-conjugated I-Ab
(clone 09/25/17), PE-conjugated CD80 (clone 16-10A1), biotin-conjugated
CD86 (clone GL1), biotin-conjugated CD69 (clone 01502D), APC-conju-
gated CD172a (clone P84), APC-conjugated CD4 (clone GK1.5) and PE-
conjugated TCR-Va2 (clone B20.1). Where necessary, cells were incu-
bated with a secondary conjugate on ice for 30 min. before washing and
resuspension for flow cytometric analysis.
Flow cytometry
Flow cytometry was performed on either a LSRII FACS machine (Becton
Dickinson) or a FACS Calibur machine (Becton Dickinson, Franklin
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Lakes, NJ, USA). BD FACSDIVA software (Becton Dickinson) was used
to set voltage parameters and event counts. For multicolour analysis,
single colour controls were used to set compensation settings on the
machine. FlowJo software (FlowJo, Ashland, Oregon, USA) was used to
analyse data. Commonly, cell debris was gated out using a forward scat-
ter (FSC) threshold of 100. Cells were further gated on the basis of side
scatter (SSC) and absence of propidium iodide (PI) staining to detect
live PI cells. Post-acquisition gating was used to obtain information on
cell subsets. Staining with isotype control antibodies or ‘fluorescence
minus one’ controls was used to set gates to distinguish specific anti-
body staining. Fluorescence-activated cell sorting was used to isolate
splenic cell subsets based on marker expression. Spleen cells were pre-
pared and stained with antibodies as described above. Sorting was per-
formed on a BD FACSAriaTM II (Becton Dickinson) cell sorter.
Enrichment of T cells
Spleens and mesenteric lymph nodes (MLN) were obtained by sterile
dissection from two mouse strains (C57BL/6.Tg(TcraTcrb)1100Mjb
(OT-I) and C57BL/6.SJL/J.OT-II.CD45.1 (OT-II)) and placed in ice-cold
modified Eagles’ medium containing 2.5% FCS (HEM2.5). Cell suspen-
sions were prepared, washed and counted as above. Cells were resus-
pended in a cocktail of antibodies specific for Mac-3 (F4/80: rat IgG2a,
j; eBioscience), CD11b (M1/70: rat IgG2b,j; eBioscience), Ter119
(TER-119: rat IgG2b,j; eBioscience), Gr-1 (RB6-8C5: rat IgG2b,j; eBio-
science), major histocompatability complex class II (MHC-II; I-A/I-E;
M5/114: rat IgG2b,j; eBioscience), and either CD4 (GK1.5: rat IgG2b,j;
BD Pharmingen, BD Biosciences, North Ryde, NSW, Australia) or CD8a
(53-6.7: rat IgG2a,j; BD Pharmingen). Hereafter, CD8a will be referred
to as CD8. Cells were incubated on ice before washing and incubation
with pre-washed goat anti-rat BioMag magnetic beads (Qiagen, Clifton
Hill, VIC, Australia). Tubes were incubated for 20 min. at 4°C with con-
stant agitation. Additional HEM2.5 medium was added to cells and
tubes placed on the magnet for at least 5 min. Unbound liquid was
transferred to a fresh tube. Mouse tonicity PBS (MTPBS) was added as
a column wash and cells resuspended in 10 ml MTPBS for storage on
ice. To identify the purity of enriched CD4 or CD8 T cells, antibodies to
Va2 (B20.1: rat IgG2a,k; BD Pharmingen) and either CD4 (GK1.5: rat
IgG2b,j) or CD8 (53-6.7: rat IgG2a,j; BD Pharmingen) were allowed to
bind to 100 ll aliquot of cells on ice for 30 min. before washing and
analysis using flow cytometry. Typically, cell preparations were found
to be 85–89% pure.
Enrichment of dendritic cells by T/B cell
depletion of spleen
Splenocyte preparations were made and counted as above. Cells were
washed twice with 10-ml MACS buffer (PBS/5% BSA/2 mM EDTA) and
then resuspended in MACS buffer (1 ml/108 cells) for staining using
antibodies to CD19 (eBio1D3; eBioscience), Thy1.2 (30-H12; eBio-
science) and Ter119 (TER-119; eBioscience). Cells were incubated with
antibody for 25 min. before washing twice with MACS buffer. Cells were
resuspended in 1-ml MACS buffer containing MACS anti-biotin mi-
crobeads (13 ll/108 cells; Miltenyi Biotec, North Ryde, NSW, Australia)
and incubated for 30 min. on ice. Cells were then washed, resuspended
in 500 ll MACS buffer and added on to pre-washed MACS LS col-
umns, which were washed three times with 3-ml MACS buffer. Flow-
through containing cells was collected, cells were washed and checked
for depletion by antibody staining and flow cytometry.
Enrichment of CD11c+ splenic DC
To isolate a population of CD11c+ splenic DC, splenocytes were pre-
pared as above, red blood cells were lysed, and cells were counted and
washed in MACS buffer. Cells were resuspended in MACS buffer
(500 ll/108 cells) containing anti-CD11c magnetic MACS microbeads
(10 ll/108 cells; Miltenyi Biotec) with incubation on ice for 25 min.
Cells were washed twice with 2 ml MACS buffer per 108 cells. Before
the second wash, cells were filtered through a 70 lm nylon sieve (Bec-
ton Dickinson). Collected cells were resuspended in 500 ll MACS buffer
per 108 cells, before loading onto a washed MACS LS column. The
column was washed as above to deplete unbound cells. The column
was removed from the SuperMACS magnet and labelled cells eluted
with 5 ml MACS buffer using a column plunger to apply pressure.
Culture of splenic DC
Dendritic cell populations were prepared by either T and B cell depletion
of spleen or enrichment of CD11c+ DC in spleen or sorted to give pure
DC subsets. Cells were either cultured at 2 9 106 cells/ml in a total vol-
ume of 1 ml in 24-well flat bottomed plastic plates, or at 5 9 106 cells/
ml in a total volume of 200 ll in a 96-well plate with sDMEM. In some
experiments, cultures were supplemented with EtxB wt (10 lg/ml), EtxB
HI (10 lg/ml), LPS (3.3 lg/ml) or a combination of EtxB and LPS. Cells
were then cultured for 12 hrs at 37°C in 5% CO2. The concentration
of EtxB used in vitro was consistent with previously published studies
[7, 24].
Generation of DC in Flt3 ligand-supplemented
culture
Bone marrow cells were cultured at 2 9 106 cells/ml in KDS RPMI
medium in 6-well plates (Becton Dickinson) with addition of 200 ng/ml
fms-related tyrosine kinase 3 ligand (Flt3L) derived as supernatant from
transfected Chinese hamster ovary cells. Cells were cultured undis-
turbed in 10% CO2 at 37°C for 8 days. These cultures generate both
cDC and pDC and these subsets can be delineated following antibody
staining and cell subset identification using flow cytometry [25].
T cell activation studies in CD11c-DTR-tg mice
For measurement of in vivo proliferation, cells isolated as described above
were labelled with CFSE (Molecular Probes, Eugene, OR, USA) using 1 ll
of CFSE (5-(and6-) carboxyfluorescein diacetate succinimidyl ester) stock
solution (5 mM in DMSO) per 107 cells. Vortexing was used to quickly
and evenly distribute stain among cells, followed by incubation for
10 min. at 37°C. Labelling was terminated by the addition of 10 ml ice-
cold HEM2.5 medium and cells were pelleted. Cells were washed twice
with 10 ml ice-cold HEM2.5 before resuspension at 1 9 107 cells/ml as
CD8+ Va2+ or CD4+ Va2+ T cells taking into account per cent purity deter-
mined by flow cytometry. CD11c-DTR-tg mice harbour a gene that
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encodes the DTR gene receptor (DTR) as a green fluorescent protein
(GFP) fusion protein under the control of the CD11c Itgax promoter. This
model can be used to transiently deplete mice of CD11c+ cells by adminis-
tration of small quantities of diphtheria toxin (Dtx) [26]. To deplete
CD11c+ cells, Dtx (Sigma-Aldrich) in PBS was administered i.p. at 4 ng/g
bodyweight daily for 3 days, while controls received PBS. Mice were then
vaccinated i.n. with 20 lg low-LPS OVA (Worthington Biochemical Corp,
Lakewood, NJ, USA) freshly resuspended in PBS and half the cohort
administered with 18 lg EtxB suspended in PBS consistent with doses
used previously by others [27, 28]. At the same time, mice were given
2 9 106 CFSE-stained OT-I or OT-II cells, isolated and stained as
described above and injected i.v. in 200 ll into bone marrow chimaeras.
Three days after vaccination and adoptive transfer of CFSE-labelled T
cells, mice were killed and mediastinal lymph nodes and spleens har-
vested. Splenocytes were stained for CD11c to identify CD11c depletion
level, and mediastinal lymph node cells stained for Va2 and either CD4 or
CD8, to identify adoptively transferred T cells. The per cent proliferating
cells was determined from CFSE profiles within CD8+ Va2+ or CD4+ Va2+
populations. The absolute number of proliferated T cells was determined
using the total lymph node cell count.
Statistical analysis
Data are presented as mean  SE for sample size n. Statistical signifi-
cance was determined using one-way or two-way ANOVA, or the
unpaired two-tailed Student’s t-test as appropriate; P ≤ 0.05 was
considered statistically significant. All analyses were performed with
the Prism 5.0 program (GraphPad Prism, San Diego, CA, USA). The
low yields of purified EtxB, as well as the scarcity of DC in tissues,
limited the number of replicates which could be studied in any one
experiment. For this reason, experiments were repeated two or three
times to verify results.
Results
EtxB reduces the prevalence of myeloid and DC
precursors in spleen
The effect of EtxB on dendritic and myeloid subset distribution in vivo
was investigated following the exposure of mice to EtxB and investi-
gation of changes in subset representation in spleen. C57BL/6J mice
were exposed to potential activators via the tail vein, including EtxB,
EtxB heat inactivated (HI) or PBS (control). Spleens were harvested at
24 hrs, depleted of T and B cells following lysis of red blood cells,
and assessed for the presence of known cell subsets by flow cytome-
try following antibody staining. Common dendritic and myeloid sub-
sets in spleen were identified on the basis of CD11c, CD11b, CD8 and
MHC-II expression as shown in Figure 1. These included CD8 cDC
(CD11chi CD11b+ CD8 MHC-II+), CD8+ cDC (CD11chi CD11b
CD8+ MHC-II+) and pDC (CD11clo CD11b CD8 MHC-II+) subsets,
gated as described in the literature [29, 30], along with p-preDC [31].
Myeloid cells were gated as the total population of CD11bhi CD11c
cells. L-DCs were gated based on their described phenotype as
CD11clo CD11bhi CD8 MHC-II dendritic-like cells [32]. Two further
subsets were gated for the purposes of this study: DC precursors
(CD11clo CD11blo CD8 MHC-II) and myeloid precursors (CD11blo
CD11c CD8 MHC-II).
Fig. 1 Identification of dendritic and myeloid subsets in spleen. Spleens were harvested from mice 24 hrs after receiving 18 lg EtxB, 18 lg heat
inactivated EtxB (EtxB HI) or PBS as a control by i.v. inoculation in the tail vein. T and B cell-depleted splenocytes were stained with antibodies and
propidium iodide (PI) for flow cytometric analysis. Plots from one representative experiment showing dendritic and myeloid subsets in spleen are
shown. Cell debris was gated out using FSC versus SSC, dead cells were excluded by gating PI cells, and subsets identified using a combination
of antibodies specific for CD11c, CD11b, CD8 and MHC-II. Gates were set on the basis of isotype control staining.
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In response to 24-hr EtxB treatment, only the DC and myeloid pre-
cursor subsets in spleen were found to be significantly reduced
(Fig. 2). No changes were observed at 72 hrs post-EtxB (data not
shown). This effect was EtxB-specific and was lost with EtxB heat
inactivation. By comparison, no other DC subsets, including L-DC,
pDC and cDC, were affected by treatment of mice with EtxB, although
treatment with EtxB gave a significant increase in the number of mye-
loid cells in spleen. This was lost after heat treatment of EtxB and
could reflect an inflammatory response. In resting animals, EtxB
appears to accelerate the development of DC and myeloid cells from
precursors, rather than induce a dramatic change in the representa-
tion of one or more particular subsets.
Mesenteric lymph nodes were also harvested from mice treated
as above, and dendritic and myeloid subsets were identified to assess
any changes in cell subset representation in comparison with spleen.
CD8 cDC, CD8+ cDC and pDC were identifiable based on CD11c,
CD11b, CD8 and MHC-II expression, but no other CD11b+ or CD11c+
subsets were present. However, as the relative proportion of each
subset did not change significantly at either 24- or 72-hr post-treat-
ment, data have not been shown. The decrease in DC precursor num-
bers observed in spleen did not therefore relate to any change in DC
prevalence in MLN.
EtxB increases the number of immature DC
The effect of EtxB compared with LPS as an activator of mature DC
was investigated by in vitro treatment. Spleen cells were prepared
Fig. 2 Representation of subsets in spleen.
Mature dendritic and myeloid subsets, and
dendritic and myeloid precursors, were
gated as shown in Figure 1. The propor-
tion of each cell type is shown as a per-
centage of total dendritic and myeloid
cells for nine individual mice.
Means  SE are shown by crosshairs.
Significantly different pairs at P ≤ 0.05,
P ≤ 0.01 and P ≤ 0.001 are identified by
*, ** and *** respectively.
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from mice by red blood cell lysis and T and B cell depletion. Cells
were cultured in the presence of 10 lg/ml EtxB, 10 lg/ml EtxB HI,
10 ng/ml LPS, a combination of 10 lg/ml EtxB and 10 ng/ml LPS or
the medium as a control (Nil). The concentration of EtxB and LPS
used was informed by the literature and tested in trial experiments.
An initial time course experiment over 24 hrs showed that 12 hrs
was the time at which greatest change in cell viability and marker
expression was detected after EtxB treatment (data not shown). All
subsequent experiments therefore involved a 12-hr culture. Cells were
stained for expression of CD11c, CD11b, CD8, MHC-II, CD80
and CD86 and analysed flow cytometrically. Subsets of CD8
cDC and CD8+ cDC were gated on the basis of their
CD11chi CD11b+ CD8 MHC-II+ and CD11chi CD11b CD8+ MHC-II+
phenotypes as shown in Figure 1. Expression of markers of activation
in DC, including MHC-II, CD86 and CD80, was then determined by
calculating median fluorescence intensity for MHC-II, and per cent
positive cells for CD80 and CD86. Cell viability was also measured in
terms of per cent cells excluding propidium iodide (PI).
EtxB increased cell survival in in vitro culture, while LPS showed
no specific effect on viability within 12 hrs (Fig. 3). As cell survival
was reduced following heat inactivation of EtxB, the effect seen must
be specific for EtxB. Cultures of cells treated with EtxB or EtxB + LPS
showed significantly lower expression of MHC-II compared with other
cultures (Fig. 3). Expression levels of the activation markers CD80
and CD86 were also reduced significantly after the culture of cells
with EtxB, with and without LPS (Fig. 4). These results could be
interpreted to mean that EtxB acts to reduce the turnover and activa-
tion of mature DC resulting in higher numbers of immature DC. This
could have an adjuvant effect by maintaining DC, as well as their
antigen-presenting capacity for a longer period. The absence of any
effect of LPS on DC present in spleen contrasts with the known effect
of LPS in driving the development of DC from precursors or immature
DC. However, this LPS effect is not evident within a 12-hr assay.
In further experiments, T and B cell-depleted splenocytes were
sorted for isolation of pure populations of pDC and CD8 cDC using
marker expression as shown in Figure 1. In general, CD8+ cDC were
not readily recoverable in high enough numbers to be included in
these experiments. Sorted pDC and CD8 cDC were therefore cul-
tured in vitro for 12 hrs with LPS and EtxB as described above. Cells
were stained with PI to determine cell viability and with an antibody to
detect MHC-II and CD69 expression by flow cytometry. Results
obtained were consistent with those shown in Figures 3 and 4 involv-
ing cultures of heterogeneous splenic myeloid cells. Increased cell
viability was seen for both cell types cultured with EtxB, with no
change following treatment with LPS (Fig. 5). This was associated
with reduced expression of markers of activation including MHC-II
and CD69 for pDC, and of MHC-II for CD8 cDC (Fig. 5). Again, LPS
had minimal effect on the expression of activation markers like MHC-
II and CD69 over a 12 hr assay. This confirms the distinct effect of
EtxB in supporting the viability of immature DC subsets as opposed
to activated cDC and pDC.
EtxB induces development of DC from precursors
in Flt3L-supplemented BM cultures
In vivo studies showing a reduction in the numbers of DC and
myeloid precursors following administration of EtxB (Fig. 2) were
Fig. 3 Effect of EtxB on DC survival and
maturation in vitro. Spleens of mice were
harvested, RBC were lysed and enriched for
CD11c+ cells. Cells were cultured (5 9 106
cells/ml) for 12 hrs with either 10 lg/ml
EtxB, 10 ng/ml LPS, 10 lg/ml HI EtxB, a
combination of EtxB and LPS, or medium
as a control (nil). Cells were stained with
antibodies to CD11c, CD11b, CD8, MHC-II,
CD80 and CD86, or isotype control antibod-
ies, prior to flow cytometric analysis. cDCs
and pDCs were gated on the basis of
CD11c, CD11b, CD8 and MHC-II expression
as described in Figure 1. Cell viability was
measured by staining the total cell popula-
tion with propidium iodide (PI). Expression
of MHC-II is shown as median fluorescent
intensity (MFI). Data are presented as
mean  SE of replicates shown as
crosshairs. Results from this experiment
are reflective of three similar experiments.
Significantly different comparisons at
P ≤ 0.05 and P ≤ 0.01 shown by * and **
respectively.
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interpreted to mean that EtxB acted to enhance the development
of DC from precursors. A direct test of this hypothesis was
therefore carried out. Flt3L-supplemented bone marrow cultures
were established for 8 days. Under these conditions, DC precur-
sors and immature DC have been shown to emerge [25]. Cells
were isolated after 8 days and cultured with either 10 lg/ml
EtxB, 10 ng/ml LPS, EtxB + LPS or PBS as a control (Nil) for
24 hrs. Cells produced in culture were stained with antibody for
identification of mature CD8+ cDC as CD11c+ SIRPa cells, and
for CD11c+ SIRPa+ cells, representing the combined population
of pDC and CD8 cDC. The level of CD80, CD86 and MHC-II
expression was then assessed on these subsets as a measure of
cell development and activation.
Each of the three activation markers was found to be significantly
up-regulated following the treatment of cells with EtxB, LPS or a com-
bination of EtxB + LPS (Fig. 6). CD80 CD86 MHC-IIlo cells reflect-
ing precursor or immature DC predominated in untreated cultures of
both CD11c+ SIRPa and CD11c+ SIRPa+ cells, suggesting that
treatment with either LPS or with EtxB enhanced the development of
mature DC from precursors showing higher levels of activation mark-
ers over a 24-hr assay. Small additional increases in CD80 and CD86
marker expression on CD11c+ SIRPa+ cells cultured with EtxB com-
pared with LPS were also detected, with an additive effect because of
the treatment with both. The increased maturation of DC shown here
is consistent with evidence in Figure 2 that DC precursor numbers
are reduced in spleen following EtxB treatment of mice. Clearly EtxB
acts on DC precursors, presumably inducing their development to
give DC.
Increased T cell activation since EtxB interacts
with DC
The ability of EtxB to act as an adjuvant in T cell activation was then
addressed. It has been suggested that EtxB has a direct immunomod-
ulatory effect on DC as these cells are pivotal to antigen processing
and presentation. An in vivo study was therefore undertaken using
‘CD11c depleting’ mice to determine the ability of EtxB to function as
an adjuvant in antigen presentation. This would rule out an alternative
hypothesis that EtxB interacts directly with T cells. In the CD11c-DTR/
GFP-tg mouse, a single dose of 4 ng Dtx/g bodyweight delivered i.p.
was sufficient to transiently deplete mice of CD11c+ cells within
24 hrs, with levels of CD11c+ DC recovering only after 3 days [26].
As repeated application of Dtx can lead to death in CD11c-DTR/GFP-
tg mice [27], haematopoietic chimaeras were generated by reconsti-
tuting lethally irradiated 6-week-old mice with T cell-depleted bone
marrow from CD11c-DTR/GFP-tg mice [33, 34]. Chimaeric mice were
then rested for 8–10 weeks after reconstitution before use in experi-
ments. Figure 7A shows CD11c depletion following three consecutive
Dtx treatments. Gates transferred from plots of undepleted mice to
Dtx-treated mice indicate change in CD11c versus GFP expression fol-
lowing DC depletion.
To assess the effect of EtxB on antigen presentation for CD4+ and
CD8+ T cell activation, T cells from OT-II and OT-I TCR-tg specific for
OVA323-339 and OVA257-264 (SIINFEKL) [35, 36] were labelled with
CFSE and adoptively transferred separately into chimaeric CD11c-
DTR/GFP-tg mice pre-primed with OVA in the presence and absence
of EtxB. Adoptively transferred T cells were identified in draining
Fig. 4 Effect of EtxB on DC activation sta-
tus. Cells were prepared, cultured and
analysed as described in Figure 3. Expres-
sion of the CD80 and CD86 markers of
DC activation was measured in terms of
% cells showing antibody staining. Data
are presented as mean  SE of duplicates
or triplicates shown as crosshairs. Results
are representative of three similar experi-
ments. Significantly different comparisons
at P ≤ 0.05, P ≤ 0.01 and P ≤ 0.001 are
shown by *, ** and *** respectively.
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mediastinal lymph node by staining for CD4 or CD8, and Va2. Both
OT-I and OT-II cells express the Va2 TCRa chain. The CFSE profile of
Va2+ CD8+/CD4+ cells was then used to assess T cell proliferation.
These results showed that following OVA + EtxB administration to
mice, CD8+ OT-I T cells exhibited greater levels of proliferation com-
pared with OT-I T cells exposed to OVA alone. This effect was lost in
two of three Dtx-treated animals depleted of CD11c (Fig. 7B). A simi-
lar effect was observed for CD4+ OT-II T cells, with CD11c ablation
almost completely negating the adjuvanting effects of EtxB (Fig. 7B).
Discussion
Previously, EtxB was shown to be a potent adjuvant for T cell
activation, although the effect of this adjuvant on DC function was
not known. Here, mice were treated with purified EtxB and the
effect on DC subsets investigated in vivo. The relative prevalence
of dendritic and myeloid subsets in spleen was found to be unaf-
fected by EtxB treatment, with the exception of a decrease in per-
centages of DC and myeloid precursors. One interpretation of this
result is that EtxB hastens the maturation of precursors in spleen,
thus leaving reduced numbers of precursors. As the overall num-
ber of mature DC and myeloid cells in spleen or MLN remained
constant, this also suggests that EtxB may increase the rate of
turnover of these cells. This explanation does not preclude the
possibility that newly formed mature DC have migrated into blood
or other lymphoid organs following EtxB administration. Another
explanation could be that, EtxB modulates precursors in bone
marrow, slowing either their development, or their migration into
blood and spleen.
Fig. 5 Direct effect of EtxB on sorted DC
subsets in culture. Sorted subsets of
CD11c+ CD11b CD8 (pDC) and
CD11chi CD11b+ CD8 (CD8 cDC) cells
were cultured for 12 hrs with either
10 lg/ml EtxB or EtxB HI, 10 ng/ml LPS,
a combination of EtxB and LPS, or med-
ium as a control. Collected cells were then
stained with antibodies to CD11c, CD11b,
CD8, MHC-II and CD69 for flow cytomet-
ric analysis. Isotype control antibodies
were used to set gates and to determine
% positive cells. Propidium iodide (PI)
staining was used to detect % live (PI)
cells. MHC-II expression was determined
as MFI. Expression of CD69 is shown in
terms of % cells staining. Data are pre-
sented as mean  SE of duplicates or
triplicates shown as crosshairs. Results
are representative of two separate experi-
ments. Significantly different pairs of data
at P ≤ 0.05, P ≤ 0.01 and P ≤ 0.001 are
represented by *, ** and *** respec-
tively.
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The effects of EtxB on DC and myeloid subsets in vivo in resting
animals are small and conservative, and are thought to be reflective
of the effect of EtxB on DC development and function in the absence
of an inflammatory stimulus. Previous studies involving inflammatory
DC in a disease model (see e.g. ref. no 38) fall short of analysing the
direct interaction between EtxB or cholera toxin (Ctx) and resting DC
subsets as well as their immune function.
Current wisdom is that inflammatory agents like LPS activate
DC leading to up-regulation of markers like CD80, CD86 and
MHC-II which subsequently influence antigen-presenting ability.
The effect of EtxB on the activation state of mature APC was
therefore assessed by monitoring changes in the expression of
activation markers following in vitro culture of freshly isolated
CD11c+ splenocytes. For each of the mature DC subsets including
pDC, CD8+ cDC and CD8 cDC, EtxB treatment was found to sig-
nificantly reduce expression of MHC-II, CD80 and CD86 at 12-hr
post-treatment (Figs 2 and 3). By 24 hrs after treatment, expres-
sion of these markers was equivalent in both treated and
untreated cultures, suggesting that EtxB induces a transient
change. This was not found for LPS which did not change the
activation status of these mature DC subsets. While a recent
report showed that LPS mediates down-regulation of CD11c on
DC cultured in vitro [37], it was also found that EtxB did not
alter CD11c or CD11b expression on splenic dendritic and mye-
loid cells in vivo (Fig. 1). Similar results were observed when
sorted pDC and CD8 cDC were exposed to EtxB in culture, and
likely reflects the ability of EtxB to delay or reduce culture-
induced activation of cells (Fig. 5).
The combination of increased cell viability and reduced activa-
tion could prolong the antigen presentation capacity of DC and
consequently manifest as an adjuvant effect because of increased
T cell activation. Indeed, this interpretation is not without prece-
dent, as similar reports of EtxB increasing the viability and sur-
vival of B cells and macrophages for delayed antigen presentation
have been reported [14, 39]. An alternative interpretation of the
in vitro results could be that an increase in cell viability and a
reduction in expression of activation markers is because of
increased maturation of DC. This could also be reflected as
increased development of DC from precursors following adminis-
tration of EtxB in vivo.
Fig. 6 Effect of EtxB on development of
DC in bone marrow cultures supple-
mented with Flt3L. Bone marrow cells
were treated to lyse red blood cells and
cultured (2 9 106 cells/ml) in 200 ng/ml
Flt3L for 8 days to induce DC develop-
ment. The total cell population was then
collected and incubated for 24 hrs with
either EtxB (10 lg/ml), LPS (10 ng/ml), a
combination of EtxB and LPS, or medium
as a control. Cells were then collected and
stained for CD11c and SIRPa to detect
the CD11c+ SIRPa subset containing pDC
and CD8 cDC, and the CD11c+ SIRPa
subset containing CD8+ cDC. Cells were
stained for detection of the activation
markers CD80, CD86 and MHC-II by flow
cytometry. Isotype control antibodies were
used to set gates. MHC-II expression was
measured in terms of MFI, and expression
of CD80 and CD86 as % cells staining.
Data are shown as mean  SE of
duplicates represented as crosshairs.
Significant differences between pairs at
P ≤ 0.05, P ≤ 0.01 and P ≤ 0.001 are
shown by *, ** and *** respectively.
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All experiments exploring the effect of EtxB on DC activation and
turnover also included LPS as a control, as it is a known and potent
activator of DC. Importantly, experiments involving a combination of
both EtxB and LPS showed a dominant effect of EtxB over LPS. This
confirms that EtxB is acting through a different signalling pathway to
LPS which is known to bind toll-like receptors on cells. These results
also showed the more powerful effect of EtxB over LPS on mature
splenic DC.
Heat inactivated EtxB also served as an effective negative control.
Another suitable negative control could also be the G33D mutant of
EtxB which no longer binds Gm1 ganglioside [2]. This mutant is
unable to induce EtxB-specific antibodies or influenza antigen-specific
A
B C* ** **
Fig. 7 EtxB acts through DC to modulate T cell activation. Mice were lethally irradiated and reconstituted with 5 9 106 T cell-depleted bone marrow
cells from CD11c-DTR/GFP-tg mice. Chimaeras were then rested for 10 weeks. Diphtheria toxin (Dtx) was injected i.p. at 4 ng/g bodyweight daily
for 3 days to deplete CD11c+ cells in chimaeras. Control mice received PBS. Mice were vaccinated i.n. on the first day with either OVA or OVA +
EtxB. (A) Splenocytes from Dtx-treated and PBS-treated (control) CD11c-Dtx/GFP-tg chimaeric mice are stained for CD11c to confirm depletion of
CD11c+ DC. Isotype control antibodies were used to set gates. (B) To assess T cell activation because of EtxB, 2 9 106 CFSE-labelled CD8+ OT-I or
CD4+ OT-II TCR-tg T cells were adoptively transferred i.v. into chimaeras. After 3 days, mediastinal lymph nodes were harvested and cells stained
with propidium iodide (PI), and for TCR-Va2, as well as CD8 or CD4, for flow cytometric analysis. Leukocytes were gated initially on the basis of
forward and side scatter (FSC, SSC), then live (PI) cells were gated to detect Va2+ TCR-tg T cells for CFSE analysis. Number of proliferated T cells
was calculated for groups of three or four mice. Number of proliferated OT-I or OT-II cells was determined by multiplying the total number of lymph
node cells by the percentage of live, Va2+ CD4+ OT-II or Va2+ CD8+ OT-I T cells which had proliferated. Pairs of data significant at P ≤ 0.05 and
P ≤ 0.01 are shown by * and **, with means and standard error of measurements shown as crosshairs.
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IgA responses compared with wild-type EtxB [2]. However, attempts
to purify both the H57A and the G33D mutant of EtxB which lack Gm1
ganglioside binding have been unsuccessful in this lab. Purification
was not pursued because of low yields and high endotoxin contami-
nation. Purification of mutants is, however, a future goal for assess-
ment of the interaction of EtxB with mature DC and for investigation
of EtxB immunomodulatory effects.
In contrast to mature DC in vivo, DC precursors isolated from
Flt3L-supplemented bone marrow cultures exhibited increased matu-
ration following EtxB treatment. The response of DC to EtxB treatment
therefore appears to depend on the maturity of the APC. Again, the
effect of EtxB on cells occurred independently of LPS. These different
effects of EtxB on mature versus immature DC could also reflect
differing levels of GM1 expression on the DC surface, a factor that
warrants further investigation.
Finally, we also investigated whether EtxB-induced changes in
the number of DC precursors, cell viability and activation marker
expression on DC in vivo translated into changes in T cell activa-
tion. In an in vivo model for antigen delivery and presentation to
OVA-specific TCR-tg T cells, EtxB did act as an adjuvant, show-
ing significant OT-I and OT-II proliferation in normal mice over
CD11c-depleted mice. The observation of EtxB-induced OT-I pro-
liferation contrasts with previous reports of EtxB inducing apopto-
sis in CD8+ T cells [40], although those experiments involved
in vitro exposure to EtxB. Comparison of responses in CD11c-
depleted versus normal mice confirmed the action of EtxB
through direct interaction with cells. Those experiments high-
lighted the importance of CD11c+ DC in CD4+ T cell responses.
This was less prominent for CD8+ T cells, but could be because
of the presence of other MHC-I-bearing cells able to present
antigen, particularly if the adoptively transferred T cells contained
a population of memory T cells [41]. In these experiments, only
cellular proliferation was investigated. In other studies, EtxB was
found to induce regulatory T cells [42], so further studies will
investigate the phenotype and cytokine production of proliferating
OT-I and OT-II cells to determine the type of T cell induced by
EtxB-treated APC. One consideration is that CD11c is also
expressed on other cell types including NK subsets with antigen-
presenting capacity [43], and on some T cells, including regula-
tory CD8+ T cells [44]. This should be taken into consideration
in interpreting results in terms of a direct role for CD11c+ DC in
mediating the EtxB effect.
The AB toxins are a class which includes Dtx, Ctx and heat-
labile enterotoxin EtxB, under study here. Both Ctx and EtxB are
similar in that their immunomodulatory capacity is mediated by
the B subunit. Both have been shown to drive a Th1 inflamma-
tory response to a Th2 response, making them targets for the
control of autoimmune and inflammatory diseases [45]. Most
studies on the effect of toxins on DC have involved Ctx which
enhances CD80 and CD86 costimulatory expression on murine DC
[46]. Cholera toxin also suppresses production of IL-12 by bone
marrow-derived DC, which drives Th1 responses [47], and
induces production of IL-6 and IL-10 important in Th2 differentia-
tion. As shown here for EtxB, the adjuvant activity of CtxB is
directly dependent on Gm1 ganglioside binding to cDC [48].
Direct contact between cDC and Ctx was shown to be essential
for adjuvant-mediated expansion of CD4+ T cells. Upon cDC
depletion, CD4+ T cell expansion was found to be halted [48].
While several studies have considered the effect of the closely
related CtxB on DC, the effect of EtxB has not previously been
evaluated in the literature. Here, EtxB has been shown to enhance
the activation of both CD8+ and CD4+ T cells, consistent with its
reported potent adjuvant activity [28]. However, CtxB was found
to only moderately enhance T cell responses [10], although
chemical conjugation of CtxB to antigen did enhance the response
further [49]. Here, it has been found that DC are essential to the
EtxB adjuvant effect.
One drawback with animal models for depletion of DC on the
basis of CD11c expression is that CD11c is an imperfect marker.
Multiple cell types including splenic metallophilic macrophages,
marginal zone macrophages, alveolar macrophages, natural killer
cells and plasmablasts are affected where the CD11c/Itgax pro-
moter is used to deplete CD11c+ cells in mice [50–53]. Here, the
proliferation of T cells was assessed in the mediastinal lymph
node following intranasal vaccination which precludes splenic mar-
ginal zone and metallophilic macrophage involvement, and alveolar
macrophages found in pulmonary alveoli. It does not exclude
plasmablasts or natural killer cells in the mediastinal lymph node.
However, the CD11c/Itgax promoter-DTR-tg mouse strain repre-
sents a powerful tool to investigate the requirement for CD11c+
cells in in vivo immune responses.
In summary, EtxB is a potent adjuvant capable of activating T
cells, which has the effect of inducing the development and matura-
tion of DC rather than their activation, as well as increasing their via-
bility. This could mean that EtxB treatment leads to more prolonged
presentation of antigen to T cells, and greater T cell activation. EtxB
also shows potential as a therapeutic agent, as it showed no toxicity
towards DC, and only minor conservative changes in DC populations
were evident.
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